Poor responders: Does the protocol make a difference?

Current Opinion in Obstetrics and Gynecology

Volumn 14, Issue 3, 2002, Pages 275-281

  Mahutte, Neal G ^a   Arici, Aydin ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADOTROPIN DERIVATIVE; GROWTH HORMONE; RECOMBINANT FOLLITROPIN;

ANEUPLOIDY; CELL NUCLEUS TRANSPLANTATION; CELL TRANSFER; CLINICAL PROTOCOL; DRUG RESPONSE; EMBRYO TRANSFER; FERTILIZATION IN VITRO; HUMAN; INFERTILITY THERAPY; OOCYTE; OOCYTE DONATION; OVULATION INDUCTION; PREGNANCY RATE; PREIMPLANTATION EMBRYO; PRIORITY JOURNAL; REVIEW; SCREENING;

CLINICAL PROTOCOLS; FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HUMANS; INFERTILITY, FEMALE; PREGNANCY; RANDOMIZED CONTROLLED TRIALS; TREATMENT FAILURE;

EID: 0036266241     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-200206000-00005     Document Type: Review

References (64)

1. A rational approach to the management of low responders in in-vitro ferlilization
2. Improved controlled ovarian hyperstimulation in poor responder in vitro fertilization patients with a microdose follicle-stimulating hormone flare, growth hormone protocol
3. Comparison of 'poor' responders with 'good' responders using a standard buserelin/human menopausal gonadotrophin regime for in-vitro fertilization
4. Evaluation and treatment of low responders in assisted reproductive technology: A challenge to meet
5. Evaluating strategies for improving ovarian response of the poor responder undergoing assisted reproductive techniques
6. Use of growth hormone-releasing factor in ovulation induction in poor responders
7. Limited success using the 'flare' protocol in poor responders in cycles with low basal follicle-stimulating hormone levels during in vitro fertilization
8. Serum levels of luteinizing and follicle-stimulating hormones in normal and poor-responding patients undergoing ovarian stimulation with urofollitropin after pituitary downregulation
9. Enhancement of ovarian responsiveness with microdoses of gonadotropin-releasing hormone agonist during ovulation induction for in vitro fertilization
10. Clinical and endocrine effects of a microdose GnRH agonist flare regimen administered to poor responders who are undergoing in vitro fertilization
11. High doses of gonadotrophins combined with stop versus non-stop protocol of GnRH analogue administration in low responder IVF patients: A prospective, randomized, controlled trial
12. Cessation of gonadotropin-releasing hormone analogue (GnRH-a) upon down-regulation versus conventional long GnRH: A protocol in poor responders undergoing in vitro fertilization
13. Comparison of agonistio flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: Results of a prospective randomized trial
14. Clinical pregnancy rates in an IVF program: Use of the flare-up protocol after failure with long regimens of GnRH-a
15. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: A case series
16. Recombinant follicle stimulating hormone is effective in poor responders to highly purified follicle stimulating hormone
17. Outcome of in-vitro fertilization through natural cycles in poor responders
18. IVF: Induction of ovulation in poor responders
19. High-dose follicle-stimulating hormone (FSH) ovarian stimulation in low-responder patients for in vitro fertilization
20. High-dose follicle-stimulating hormone stimulation at the onset of the menstrual cycle does not improve the in vitro fertilization outcome in low-responder patients
21. The value of increasing the dose of human menopausal gonadotropins in women who initially demonstrate a poor response
22. High-dose human menopausal gonadotropin stimulation in poor responders does not improve in vitro fertilization outcome
23. Recombinant follicle stimulating hormone stimulation in poor responders with normal basal concentrations of follicle stimulating hormone and oestradiol: Improved reproductive outcome
24. HMG is as good as recombinant human FSH in terms of oocyte and embryo quality: A prospective randomized trial
25. Human menopausal gonadotropin versus recombinant follicle-stimulating hormone in normogonadotropic women down-regulated with a gonadotropin-releasing hormone agonist who were undergoing in vitro fertilization and intracytoplasmic sperm injection: A prospective randomized study
26. A randomized prospective assessor-blind evaluation of luteinizing hormone dosage and in vitro fertilization outcome
27. Rescue of IVF cycles by HMG in pituitary down-regulated normogonadotrophic young women characterized by a poor initial response to recombinant FSH
28. The use of biosynthetic human growth hormone to augment ovulation induction with buserelin acetate/human menopausal gonadotropin in women with a poor ovarian response
29. Interest of growth hormone-releasing hormone administration for improvement of ovarian responsiveness to gonadotropins in poor responder women
30. The value of human growth hormone as an adjuvant for ovarian stimulation in a human in vitro fertilization program
31. Another look at co-treatment with growth hormone and human menopausal gonadotrophins in poor ovarian responders
32. A double-blind cross-over controlled study to evaluate the effect of human biosynthetic growth hormone on ovarian stimulation in previous poor responders to in-vitro fertilization
33. Double-blind placebo controlled study: Human biosynthetic growth hormone for assisted reproductive technology
34. Does growth hormone-releasing factor assist follicular development in poor responder patients undergoing ovarian stimulation for in-vitro fertilization?
35. GnRH receptors in human granulosa cells: Anatomical localization and characterization by autoradiographic study
36. Ovarian estradiol production in vivo: Inhibitory effect of leuprolide acetate
37. Minidose gonadotropin-releasing hormone agonist is the treatment of choice in poor responders with high follicle-stimulating hormone levels
38. A protocol using a low dose of gonadotrophin-releasing hormone agonist might be the best protocol for patients with high follicle-stimulating hormone concentrations on day 3
39. Cessation of gonadotropin-releasing hormone agonist therapy combined with high-dose gonadotropin stimulation yields favorable pregnancy results in low responders
40. Will GnRH antagonists provide new hope for patients considered 'difficult responders' to GnRH agonist protocols?
41. Assisted hatching by partial zona dissection of human pre-embryos in patients with recurrent implantation failure after in vitro fertilization
42. Implantation enhancement by selective assisted hatching using zona drilling of human embryos with poor prognosis
43. Assisted hatching in the treatment of poor prognosis in vitro fertilization candidates
44. Rescue of implantation potential in embryos with poor prognosis by assisted zona hatching
45. Transfer of zona-free embryos improves outcome in poor prognosis patients: A prospective randomized controlled study
46. Assisted hatching by zona drilling of human embryos in women of advanced age
47. A prospective, randomized, double-blind study for the evaluation of assisted hatching in patients with advanced maternal age
48. A study failing to determine significant benefits from assisted hatching: Patients selected for advanced age, zonal thickness of embryos, and previous failed attempts
49. Does assisted hatching improve implantation rates after in vitro fertilization or intracytoplasmic sperm injection in all patients? A prospective randomized study
50. Will preimplantation genetic diagnosis assist patients with a poor prognosis to achieve pregnancy?
51. Incidence of chromosomal abnormalities from a morphologically normal cohort of embryos in poor-prognosis patients
52. Chromosomal abnormalities in embryos
53. Preimplantation diagnosis for aneuploidies in patients undergoing in vitro fertilization with a poor prognosis: Identification of the categories for which it should be proposed
54. Poor responders to ovarian hyperstimulation may benefit from an attempt at natural-cycle oocyte retrieval
55. Maturation of human oocytes in vitro and their developmental competence
56. Pregnancies and deliveries after in vitro maturation culture followed by in vitro fertilization and embryo transfer without stimulation in women with polycystic ovary syndrome
57. The potential use of maturation in vitro of human oocytes in low responder patients
58. Maturation and apoptosis of human oocytes in vitro are age-related
59. Follicular development in vitro
60. Cryopreservation and culture of human primordial and primary ovarian follicles
61. Mitochondrial deoxyribonucleic acid deletions in oocytes and reproductive aging in women
62. Ooplasmic transfer in mature human oocytes
63. Mitochondria in human offspring derived from ooplasmic transplantation
64. Fertility and maternal age strategies to improve pregnancy outcome